Exenatide is a licensed and effective treatment for type 2 diabetes
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer
However, like most therapies targeting metabolic pathways, they are not free of risks
Their primary therapeutic actions include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying to promote satiety, and acting on hypothalamic appetite centers to reduce hunger and caloric intake
While this is primarily a concern for medications with a narrow therapeutic index, corticosteroids are not typically affected
The sublingual semaglutide guide covers absorption, effectiveness, and proper administration technique